Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

42180 reported adverse events

Drugs of this class: EFAVIRENZ NEVIRAPINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ETRAVIRINE DORAVIRINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 7421
1 CHRONIC KIDNEY DISEASE 4446
2 RENAL INJURY 3982
3 TOOTH LOSS 3799
4 PAIN 3726
5 RENAL FAILURE 3611
6 EMOTIONAL DISTRESS 3535
7 SKELETAL INJURY 3534
8 OSTEONECROSIS 3472
9 BONE LOSS 3431
See all common reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 86 0.8113
1 CONGENITAL NEOPLASM 19 0.7917
2 HEPATIC DISPLACEMENT 17 0.7727
3 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 143 0.6976
4 DIAPHRAGMATIC APLASIA 18 0.6923
5 PINEALOBLASTOMA 49 0.5444
6 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 36 0.5000
7 CLOACAL EXSTROPHY 26 0.4906
8 TOOTH INJURY 1474 0.4857
9 BLADDER AGENESIS 31 0.4844
See all enriched reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]